Latest & greatest articles for urinary tract infection

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on urinary tract infection or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on urinary tract infection and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for urinary tract infection

1. Management of suspected bacterial lower urinary tract infection in adult women

use, patients should be thoroughly evaluated for the source of signs and symptoms before attributing them to the urinary tract. The presence of bacteria in the urine of catheterised patients is common and inevitable but ASB does not necessarily indicate presence of infection. 6 | Catheter-associated lower urinary tract infection in women35 Management of suspected bacterial lower urinary tract infection in adult women The following statements are reproduced, with permission, from The Infectious (...) Management of suspected bacterial lower urinary tract infection in adult women Management of suspected bacterial lower urinary tract infection in adult women A national clinical guideline September 2020 SIGN160Key to evidence statements and recommendations Levels of evidence 1 ++ High-quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias 1 + Well-conducted meta-analyses, systematic reviews, or RCTs with a low risk of bias 1 – Meta-analyses, systematic reviews

2020 SIGN

2. Acupuncture for recurrent urinary tract infection in women: a systematic review and meta-analysis

Acupuncture for recurrent urinary tract infection in women: a systematic review and meta-analysis Acupuncture for recurrent urinary tract infection in women: a systematic review and meta-analysis - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. National Institutes of Health National Library of Medicine National Center (...) Copy Actions Cite Share Permalink Copy Page navigation Review BJOG Actions . 2020 May 14. doi: 10.1111/1471-0528.16315. Online ahead of print. Acupuncture for recurrent urinary tract infection in women: a systematic review and meta-analysis , , , , , , , , , , Affiliations Expand Affiliations 1 The Second Affiliated Hospital of Guangzhou University of Chinese Medicine (Guangdong Provincial Hospital of Chinese Medicine), Guangdong Provincial Academy of Chinese Medical Sciences and The Second

2020 EvidenceUpdates

3. Urinary tract infections in children. (Abstract)

Urinary tract infections in children. Urinary tract infections (UTIs) in children are among the most common bacterial infections in childhood. They are equally common in boys and girls during the first year of life and become more common in girls after the first year of life. Dividing UTIs into three categories; febrile upper UTI (acute pyelonephritis), lower UTI (cystitis), and asymptomatic bacteriuria, is useful for numerous reasons, mainly because it helps to understand the pathophysiology (...) of the infection. A single episode of febrile UTI is often caused by a virulent Escherichia coli strain, whereas recurrent infections and asymptomatic bacteriuria commonly result from urinary tract malformations or bladder disturbances. Treatment of an upper UTI needs to be broad and last for 10 days, a lower UTI only needs to be treated for 3 days, often with a narrow-spectrum antibiotic, and asymptomatic bacteriuria is best left untreated. Investigations of atypical and recurrent episodes of febrile UTI

2020 Lancet

4. Recurrent Lower Urinary Tract Infections in Females

Recurrent Lower Urinary Tract Infections in Females Date of origin: 1995 Last review date: 2014 ACR Appropriateness Criteria ® 1 Recurrent Lower UTIs in Women American College of Radiology ACR Appropriateness Criteria ® Clinical Condition: Recurrent Lower Urinary Tract Infections in Women Variant 1: “Uncomplicated” with no underlying risk factors. Radiologic Procedure Rating Comments RRL* CT abdomen and pelvis without and with IV contrast 2 ???? X-ray abdomen 2 ?? CT abdomen and pelvis without (...) ; 7,8,9 Usually appropriate *Relative Radiation Level ACR Appropriateness Criteria ® 2 Recurrent Lower UTIs in Women Clinical Condition: Recurrent Lower Urinary Tract Infections in Women Variant 2: “Complicated,” or patients who are nonresponders to conventional therapy, get frequent reinfections or relapses, and have known underlying risk factors. (See Appendix 1.) Radiologic Procedure Rating Comments RRL* CT abdomen and pelvis without and with IV contrast 7 CT urography protocol is preferred

2020 American College of Radiology

5. Cefiderocol (Fetroja) - urinary tract infections

Cefiderocol (Fetroja) - urinary tract infections Drug Approval Package: FETROJA (cefiderocol) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: FETROJA (cefiderocol) Company: Shionogi, Inc. Application Number: 209445Orig1s000 Approval Date: 11/14/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF

2020 FDA - Drug Approval Package

6. Point-of-Care Urine Dipstick Testing for Suspected Urinary Tract Infections for Adults: Diagnostic Accuracy

Point-of-Care Urine Dipstick Testing for Suspected Urinary Tract Infections for Adults: Diagnostic Accuracy Point-of-Care Urine Dipstick Testing for Suspected Urinary Tract Infections for Adults: Diagnostic Accuracy | CADTH.ca Find the information you need Point-of-Care Urine Dipstick Testing for Suspected Urinary Tract Infections for Adults: Diagnostic Accuracy Point-of-Care Urine Dipstick Testing for Suspected Urinary Tract Infections for Adults: Diagnostic Accuracy Last updated: February 15 (...) , 2019 Project Number: RA1013-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the comparative diagnostic accuracy of point-of-care urine dipstick testing versus microscopic urinalysis in adult patients who present urinary tract infections in the emergency room or primary care setting? Key Message One systematic review and twp non-randomized studies were identified regarding point-of-care urine dipstick testing for suspected urinary

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

7. Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Fluoroquinolones for the Treatment of Urinary Tract (...) Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last updated: April 26, 2019 Project Number: RC1101-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness of fluoroquinolones for the treatment of urinary tract infections? What is the cost-effectiveness of fluoroquinolones for the treatment of urinary tract infections? What are the evidence-based guidelines regarding the use

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

8. Coated Catheters to Reduce Urinary Tract Infections: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Coated Catheters to Reduce Urinary Tract Infections: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Coated Catheters to Reduce Urinary Tract Infections: Clinical Effectiveness, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Coated Catheters to Reduce Urinary Tract Infections: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Coated Catheters to Reduce Urinary Tract Infections: Clinical Effectiveness, Cost-Effectiveness, and Guidelines Last (...) updated: April 30, 2019 Project Number: RB1323-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of coated catheters compared to standard non-coated catheters for patients requiring long-term urinary catheter use for the prevention of urinary tract infections and blockage? What is the cost-effectiveness of coated catheters compared to standard non-coated catheters for patients requiring long-term

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

9. Quantitative Results of a National Intervention to Prevent Hospital-Acquired Catheter-Associated Urinary Tract Infection: A Pre-Post Observational Study. Full Text available with Trip Pro

Quantitative Results of a National Intervention to Prevent Hospital-Acquired Catheter-Associated Urinary Tract Infection: A Pre-Post Observational Study. Many hospitals struggle to prevent catheter-associated urinary tract infection (CAUTI).To evaluate the effect of a multimodal initiative on CAUTI in hospitals with high burden of health care-associated infection (HAI).Prospective, national, nonrandomized, clustered, externally facilitated, pre-post observational quality improvement initiative (...) , for 3 cohorts active between November 2016 and May 2018.Acute care, long-term acute care, and critical access hospitals, including intensive care and non-intensive care wards.Target hospitals had a high burden of Clostridioides difficile infection plus central line-associated bloodstream infection, CAUTI, or hospital-onset methicillin-resistant Staphylococcus aureus bloodstream infection, defined as cumulative attributable differences above the first tertile in the Targeted Assessment for Prevention

2019 Annals of Internal Medicine

10. Urinary tract infection: diagnostic tools for primary care

Urinary tract infection: diagnostic tools for primary care Urinary tract infection: diagnostic tools for primary care - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search The United Kingdom is leaving the European Union on 31 October 2019. Guidance Urinary tract infection: diagnostic tools for primary care Quick reference materials for primary care on diagnosing and understanding culture results for urinary tract (...) and flowcharts for adults over-65 in the quick reference tool, which has been newly endorsed by NICE to follow guidance on managing catheter-associated urinary tract infections (CAUTI). 8 May 2019 Updated with revised UTI quick reference guide. 13 November 2018 Updated with revised UTI quick reference guide and flowcharts. 16 May 2018 Added link to the public consultation 'Diagnosis of urinary tract infections: quick reference guide'. 16 June 2017 Updated version of documents. 18 September 2014 Latest update

2019 Public Health England

11. UroShield for preventing catheter-associated urinary tract infections

UroShield for preventing catheter-associated urinary tract infections UroShield for pre UroShield for prev venting catheter-associated enting catheter-associated urinary tr urinary tract infections act infections Medtech innovation briefing Published: 9 September 2019 www.nice.org.uk/guidance/mib191 pathways Sum Summary mary The technology technology described in this briefing is UroShield. It is used to prevent catheter-associated urinary tract infections (CAUTI) in people with long-term (...) -of-rights). Page 1 of 11reduce the average number of CAUTIs per patient per year. The available evidence does not currently confirm that this would be the case. The technology The technology UroShield (NanoVibronix) is a disposable ultrasound device designed to reduce the risk of catheter- associated urinary tract infection (CAUTI). It reduces bacterial colonisation and biofilm formation on indwelling urinary catheters. UroShield should not be used for treating an active urinary infection

2019 National Institute for Health and Clinical Excellence - Advice

12. Recurrent Uncomplicated Urinary Tract Infections in Women

factors for complicated UTI, as previously discussed, should also be elucidated. Patient history should document the symptoms the patient considers indicative of a UTI, the relationship of acute episode to infectious triggers (e.g. sexual intercourse), antimicrobials used for each episode, Copyright © 2019 American Urological Association Education and Research, Inc.® Recurrent Uncomplicated Urinary Tract Infection American Urological Association (AUA)/Canadian Urological Association (CUA)/ Society (...) Recurrent Uncomplicated Urinary Tract Infections in Women 1 Purpose Over the past few decades, our ability to diagnose, treat, and manage recurrent urinary tract infection (rUTI) long-term has evolved due to additional insights into the pathophysiology of rUTI, a new appreciation for the adverse effects of repetitive antimicrobial therapy (“collateral damage”), 1 rising rates of bacterial antimicrobial resistance, and better reporting of the natural history and clinical outcomes of acute

2019 American Urological Association

13. Imipenem, cilastatin and relebactam (Recarbrio) - To treat complicated urinary tract and complicated intra-abdominal infections

Imipenem, cilastatin and relebactam (Recarbrio) - To treat complicated urinary tract and complicated intra-abdominal infections Drug Approval Package: RECARBRIO U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: RECARBRIO Company: Merck Sharp & Dohme Corp. Application Number: 212819 Approval Date: 07/16/2018 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling

2019 FDA - Drug Approval Package

14. Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. (Abstract)

Sodium-Glucose Cotransporter-2 Inhibitors and the Risk for Severe Urinary Tract Infections: A Population-Based Cohort Study. Prior studies evaluating risk for severe urinary tract infections (UTIs) with sodium-glucose cotransporter-2 (SGLT-2) inhibitors have reported conflicting findings.To assess whether patients initiating use of SGLT-2 inhibitors were at increased risk for severe UTI events compared with those initiating use of dipeptidyl peptidase-4 (DPP-4) inhibitors or glucagon-like

2019 Annals of Internal Medicine

15. Pregnancy and lower urinary tract infection: opt for cefuroxime

Pregnancy and lower urinary tract infection: opt for cefuroxime Prescrire IN ENGLISH - Spotlight ''Pregnancy and lower urinary tract infection: opt for cefuroxime'', 1 April 2019 {1} {1} {1} | | > > > Pregnancy and lower urinary tract infection: opt for cefuroxime Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight Pregnancy and lower urinary tract (...) infection: opt for cefuroxime Requiring just a single dose, fosfomycin trometamol is easier to take than cefuroxime or the combination of amoxicillin + clavulanic acid, but less is known about its short-term effects on the unborn child exposed during the first trimester of pregnancy. It is wiser to choose cefuroxime as first-line treatment. Minor lower urinary tract infections are frequent during pregnancy. They are routinely treated because they are a risk factor for premature birth. The first-choice

2019 Prescrire

16. Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study. Full Text available with Trip Pro

Antibiotic management of urinary tract infection in elderly patients in primary care and its association with bloodstream infections and all cause mortality: population based cohort study. To evaluate the association between antibiotic treatment for urinary tract infection (UTI) and severe adverse outcomes in elderly patients in primary care.Retrospective population based cohort study.Clinical Practice Research Datalink (2007-15) primary care records linked to hospital episode statistics (...) and death records in England.157 264 adults aged 65 years or older presenting to a general practitioner with at least one diagnosis of suspected or confirmed lower UTI from November 2007 to May 2015.Bloodstream infection, hospital admission, and all cause mortality within 60 days after the index UTI diagnosis.Among 312 896 UTI episodes (157 264 unique patients), 7.2% (n=22 534) did not have a record of antibiotics being prescribed and 6.2% (n=19 292) showed a delay in antibiotic prescribing. 1539

2019 BMJ

17. Once-Daily Plazomicin for Complicated Urinary Tract Infections. Full Text available with Trip Pro

Once-Daily Plazomicin for Complicated Urinary Tract Infections. The increasing multidrug resistance among gram-negative uropathogens necessitates new treatments for serious infections. Plazomicin is an aminoglycoside with bactericidal activity against multidrug-resistant (including carbapenem-resistant) Enterobacteriaceae.We randomly assigned 609 patients with complicated urinary tract infections (UTIs), including acute pyelonephritis, in a 1:1 ratio to receive intravenous plazomicin (15 mg per

2019 NEJM Controlled trial quality: predicted high

18. Urinary tract infections in women

with fever suggests pyelonephritis. Diagnosed using urine dipstick, microscopic urinalysis (bacteria, white blood cell, red blood cell), and urine culture. Antibiotic selection should be guided by local bacterial susceptibilities and guidelines, or based on known urine culture and sensitivity. Definition A urinary tract infection (UTI) is an infection of the kidneys, bladder, or urethra. Infectious cystitis is the most common type of UTI, which is caused by a bacterial infection of the bladder (...) Urinary tract infections in women Urinary tract infections in women - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Urinary tract infections in women Last reviewed: February 2019 Last updated: January 2019 Summary Can be clinically categorised into uncomplicated/complicated, acute, or recurrent. Escherichia coli is the most common organism in uncomplicated infections. Costovertebral angle tenderness together

2019 BMJ Best Practice

19. Vaccine Development for Urinary Tract Infections: Where Do We Stand? (Abstract)

Vaccine Development for Urinary Tract Infections: Where Do We Stand? Urinary tract infections (UTIs) are among the most common bacterial infections. Its management has become increasingly challenging due to antimicrobial resistance. The four mainstays to tackle this crisis rely on the development of new antibiotic agents, the introduction of preventive and alternative antimicrobial strategies, the concept of antimicrobial stewardship, and effective hygiene measures. One of the most effective (...) approaches to prevent UTIs is the design of a potent vaccine. OM-89 is a lyophilised preparation of membrane proteins from 18 different uropathogenic Escherichia coli strains. The safety and efficacy of this immunoactive agent is well documented; therefore, it is recommended for the prophylaxis of UTI according to the current European Association of Urology guidelines on urological infections. In terms of a true vaccine designed to target specifically pathogenic bacteria, no substance is currently

2019 European urology focus

20. Primary care: Single-dose fosfomycin is less effective than 5-day nitrofurantoin in women with uncomplicated urinary tract infection: closing the evidence gap for a new recommendation of an old antibiotic

Primary care: Single-dose fosfomycin is less effective than 5-day nitrofurantoin in women with uncomplicated urinary tract infection: closing the evidence gap for a new recommendation of an old antibiotic Single-dose fosfomycin is less effective than 5-day nitrofurantoin in women with uncomplicated urinary tract infection: closing the evidence gap for a new recommendation of an old antibiotic | BMJ Evidence-Based Medicine Log in using your username and password For personal accounts OR managers (...) of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Single-dose fosfomycin is less effective than 5-day nitrofurantoin in women with uncomplicated urinary tract infection: closing the evidence gap for a new recommendation of an old antibiotic Article Text Commentary

2019 Evidence-Based Medicine